KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EPS (Basic) (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed EPS (Basic) for 18 consecutive years, with $6.99 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Basic) fell 7.78% year-over-year to $6.99; the TTM value through Mar 2026 reached $42.56, up 1.89%, while the annual FY2025 figure was $43.07, 5.31% up from the prior year.
  • EPS (Basic) hit $6.99 in Q1 2026 for Regeneron Pharmaceuticals, down from $8.24 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $14.09 in Q3 2025 and bottomed at $6.7 in Q1 2024.
  • Average EPS (Basic) over 5 years is $9.92, with a median of $9.12 recorded in 2022.
  • Year-over-year, EPS (Basic) tumbled 73.23% in 2022 and then skyrocketed 46.41% in 2024.
  • Regeneron Pharmaceuticals' EPS (Basic) stood at $11.21 in 2022, then decreased by 2.85% to $10.89 in 2023, then dropped by 21.58% to $8.54 in 2024, then decreased by 3.51% to $8.24 in 2025, then decreased by 15.17% to $6.99 in 2026.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at $6.99, $8.24, and $14.09 for Q1 2026, Q4 2025, and Q3 2025 respectively.